Dendritic Cell Cancer Vaccine Market Size, Share & Trends Analysis Report By Products (CreaVax, Sipuleucel-T), By End-use (Pediatrics, Adults), By Region, And Segment Forecasts, 2023 - 2030
This report can be delivered to the clients within 3 Business Days
Dendritic Cell Cancer Vaccine Market Growth & Trends
The global dendritic cell cancer vaccine market size is expected to reach USD 1.46 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.18% from 2023 to 2030. The rising prevalence of cancer and technological improvement such as drug innovation related to cancer are driving the market growth. According to the WHO, cancer is the leading cause of mortality globally, accounting for around 10 million deaths in 2020.
Immunotherapy is a new approach that strengthens an individual’s immunity to combat different types of carcinoma. Dendritic cell-based immunotherapy vaccination is a well-known and approved approach for enhancing the potential of the immune system to eliminate tumor cells. Many studies are carried out to gauge the efficacy of dendritic cell cancer vaccines. For instance, in June 2020, UbiVac, Inc. signed into a clinical trial collaboration with Bristol Myers Squibb for evaluation of the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product (DPV-001), a dendritic cell-targeted micro-vesicle containing short-lived protein vaccine to explore autophagy, in combination with anti-OX40 (by Bristol Myers Squibb) along with sequenced administration of nivolumab.
Moreover, wide applications of cancer vaccines to boost the immune system are some of the driving factors for market growth. Cancer vaccines are appropriately recognizing and effectively react to antigens associated with carcinoma and kill the carcinogenic cells. They progressively reduce the growth of tumorous cells in the body and induce immunity in an individual to effectively cease the chances of a relapse of cancer condition.
Rising clinical trial activity along with novel product launches create the growth opportunity for market growth. As of November 2022, more than 80 dendritic cell cancer vaccines are under clinical trials. In addition, in June 2021, SPAG9, India's First Indigenous Tumor Antigen, Received a Trademark from DBT-NII. Dendritic cell (DC)-based immunotherapy is being used with ASPAGNIITM for cervical, ovarian, and breast cancers.
Furthermore, key companies in the market undertaking various strategic initiatives to introduce novel are expected to drive the market. For instance, in June 2020, Saint-Gobain Life Sciences signed into a joint collaboration with Kanyr Pharma Inc., the RI-MUHC, and McGill University for research on cancer vaccines based on dendritic cells using single-use culture containers by Saint-Gobain for R&D, clinical-scale and commercial phase production of vaccines.
Dendritic Cell Cancer Vaccine Market Report Highlights
Dendritic Cell Cancer Vaccine Market Growth & Trends
The global dendritic cell cancer vaccine market size is expected to reach USD 1.46 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.18% from 2023 to 2030. The rising prevalence of cancer and technological improvement such as drug innovation related to cancer are driving the market growth. According to the WHO, cancer is the leading cause of mortality globally, accounting for around 10 million deaths in 2020.
Immunotherapy is a new approach that strengthens an individual’s immunity to combat different types of carcinoma. Dendritic cell-based immunotherapy vaccination is a well-known and approved approach for enhancing the potential of the immune system to eliminate tumor cells. Many studies are carried out to gauge the efficacy of dendritic cell cancer vaccines. For instance, in June 2020, UbiVac, Inc. signed into a clinical trial collaboration with Bristol Myers Squibb for evaluation of the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product (DPV-001), a dendritic cell-targeted micro-vesicle containing short-lived protein vaccine to explore autophagy, in combination with anti-OX40 (by Bristol Myers Squibb) along with sequenced administration of nivolumab.
Moreover, wide applications of cancer vaccines to boost the immune system are some of the driving factors for market growth. Cancer vaccines are appropriately recognizing and effectively react to antigens associated with carcinoma and kill the carcinogenic cells. They progressively reduce the growth of tumorous cells in the body and induce immunity in an individual to effectively cease the chances of a relapse of cancer condition.
Rising clinical trial activity along with novel product launches create the growth opportunity for market growth. As of November 2022, more than 80 dendritic cell cancer vaccines are under clinical trials. In addition, in June 2021, SPAG9, India's First Indigenous Tumor Antigen, Received a Trademark from DBT-NII. Dendritic cell (DC)-based immunotherapy is being used with ASPAGNIITM for cervical, ovarian, and breast cancers.
Furthermore, key companies in the market undertaking various strategic initiatives to introduce novel are expected to drive the market. For instance, in June 2020, Saint-Gobain Life Sciences signed into a joint collaboration with Kanyr Pharma Inc., the RI-MUHC, and McGill University for research on cancer vaccines based on dendritic cells using single-use culture containers by Saint-Gobain for R&D, clinical-scale and commercial phase production of vaccines.
Dendritic Cell Cancer Vaccine Market Report Highlights
- By product, the Sipuleucel-T (Provenge) is expected to occupy the largest share of market space due to its advantages in the treatment of castrate-resistant prostate carcinoma.
- By end-use, the adult segment is expected to grow rapidly over the forecast period owing to the rise in the incidence of carcinoma across the globe. The rise in the demand for personalized medicine for the treatment of cancer, also positively impacts the growth of this segment.
- North America dominated the global market in 2022, owing to the rising prevalence of cancers, increasing healthcare expenditure, and rising support for oncology research.
- The Asia Pacific is expected to grow considerably in the future due to the rising prevalence of cancers and high population density. Moreover, key market players are working towards entering the Asia Pacific market with their dendritic cell vaccine expertise. For instance, in May 2021, BGI signed an agreement with the Ethiopian Biotechnology Institute to carry out pilot-scale testing of HPV genotyping to establish a novel technique for HPV screening, diagnosis, and treatment.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Research Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Objectives
1.6.1 Objective
1.6.2 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Dendritic Cell Cancer Vaccine Market: Market Outlook
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Trends & Outlook
3.2 Trend Analysis
3.2.1 Product Trends
3.2.1 End - Use Trends
3.3 Market Segmentation & Scope
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Rise In The Global Incidence Of Cancer Cases
3.4.1.2 Rise In The Demand For Cancer Vaccines
3.4.1.3 Increasing Healthcare Expenditure And Research Support
3.4.2 Market Restraint Analysis
3.4.2.High-Cost Factor
3.4.2.2 Potential Side Effects Caused By Cancer Vaccines
3.4.3 Opportunity Analysis
3.5 Impact of the COVID-19 Pandemic on the Dendritic Cell Cancer Vaccine Market
3.6 Penetration & Growth Prospect Mapping for Products, 2022
3.7 Business Environment Analysis
3.7.1 Dendritic Cell Cancer Vaccine Market - Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.7.2 Porter’s Five Forces Analysis
3.8 Market Share Analysis
3.8.1 Company Size
3.8.2 Product Portfolio
3.8.3 Strategic Initiatives
3.9 Competitive Landscape
3.9.1 Strategy Framework
3.9.2 Market Participation Categorization
3.9.2.1 New/ Emerging Entrants
3.9.2.2 Mature Players & Leaders
CHAPTER 5 PRODUCTS BUSINESS ANALYSIS
5.1 Creavax
5.1.1 Global Dendritic Cell Cancer Vaccine Market For Creavax, 2018 - 2030 (USD Million)
5.2 Sipuleucel - T (Provenge)
5.2.1 Global Dendritic Cell Cancer Vaccine Market For Sipuleucel - Y (Provenge), 2018 - 2030 (USD Million)
5.3 Others
5.3.1 Global Dendritic Cell Cancer Vaccine Market For Others, 2018 - 2030 (USD Million)
CHAPTER 6 END-USE BUSINESS ANALYSIS
6.1 Pediatrics
6.1.1 Global Dendritic Cell Cancer Vaccine Market For Pediatrics, 2018 - 2030 (USD Million)
6.2 Adults
6.2.1 Global Dendritic Cell Cancer Vaccine Market For Adults, 2018 - 2030 (USD Million)
CHAPTER 8 REGIONAL BUSINESS ANALYSIS
8.1 Dendritic Cell Cancer Vaccine Market: Regional Movement Analysis, 2021 & 2030
8.2 North America
8.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
8.2.3 Canada
8.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3 Europe
8.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.2 Germany
8.3.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
8.3.3 UK
8.3.3.1 UK market estimates and forecast, 2018 - 2030 (USD Million)
8.3.4 France
8.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.5 Italy
8.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.6 Spain
8.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.7 Denmark
8.3.7.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.8 Sweden
8.3.8.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.8 Norway
8.3.8.1 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4 Asia - Pacific
8.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.2 Japan
8.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.3 China
8.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.4 India
8.4.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.5 Australia
8.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.6 Thailand
8.4.5.1 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.6 South Korea
8.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5 Latin America (Latam)
8.5.1 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5.4 Argentina
8.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6 Middle East and Africa (MEA)
8.6.1 Middle East And Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.4 Uae
8.6.4.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.4 Kuwait
8.6.4.1 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
CHAPTER 9 COMPANY PROFILES
9.1 Company Profiles
9.1.1 3M COMPANY
9.1.1.1 Company Overview
9.1.1.2 Financial Performance
9.1.1.3 Product Benchmarking
9.1.1.4 Strategic Initiatives
9.1.2 GLAXOSMITHKLINE PLC
9.1.2.1 Company Overview
9.1.2.2 Financial Performance
9.1.2.3 Product Benchmarking
9.1.2.4 Strategic Initiatives
9.1.3 ACTIVARTIS
9.1.3.1 Company Overview
9.1.3.2 Financial Performance
9.1.3.3 Product Benchmarking
9.1.3.4 Strategic Initiatives
9.1.4 BATAVIA BIOSERVICES
9.1.4.1 Company Overview
9.1.4.2 Financial Performance
9.1.4.3 Product Benchmarking
9.1.4.4 Strategic Initiatives
9.1.5 ARGOS THERAPEUTICS
9.1.5.1 Company Overview
9.1.5.2 Financial Performance
9.1.5.3 Product Benchmarking
9.1.5.4 Strategic Initiatives
9.1.6 SANPOWER CORPORATION
9.1.6.1 Company Overview
9.1.6.1 Financial Performance
9.1.6.2 Product Benchmarking
9.1.6.3 Strategic Initiatives
9.1.7 ELIOS THERAPEUTICS
9.1.7.1 Company Overview
9.1.7.2 Financial Performance
9.1.7.3 Product Benchmarking
9.1.7.4 Strategic Initiatives
9.1.8 DANDRIT BIOTECH
9.1.8.1 Company Overview
9.1.8.2 Financial Performance
9.1.8.3 Product Benchmarking
9.1.8.4 Strategic Initiatives
9.1.9 DCPRIME
9.1.9.1 Company Overview
9.1.9.2 Financial Performance
9.1.9.3 Product Benchmarking
9.1.9.4 Strategic Initiatives
9.1.10 IMMUNOCELLULAR THERAPEUTICS
9.1.10.1 Company Overview
9.1.10.2 Financial Performance
9.1.10.3 Product Benchmarking
9.1.10.4 Strategic Initiatives
1.1 Research Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Objectives
1.6.1 Objective
1.6.2 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Dendritic Cell Cancer Vaccine Market: Market Outlook
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Trends & Outlook
3.2 Trend Analysis
3.2.1 Product Trends
3.2.1 End - Use Trends
3.3 Market Segmentation & Scope
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Rise In The Global Incidence Of Cancer Cases
3.4.1.2 Rise In The Demand For Cancer Vaccines
3.4.1.3 Increasing Healthcare Expenditure And Research Support
3.4.2 Market Restraint Analysis
3.4.2.High-Cost Factor
3.4.2.2 Potential Side Effects Caused By Cancer Vaccines
3.4.3 Opportunity Analysis
3.5 Impact of the COVID-19 Pandemic on the Dendritic Cell Cancer Vaccine Market
3.6 Penetration & Growth Prospect Mapping for Products, 2022
3.7 Business Environment Analysis
3.7.1 Dendritic Cell Cancer Vaccine Market - Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.7.2 Porter’s Five Forces Analysis
3.8 Market Share Analysis
3.8.1 Company Size
3.8.2 Product Portfolio
3.8.3 Strategic Initiatives
3.9 Competitive Landscape
3.9.1 Strategy Framework
3.9.2 Market Participation Categorization
3.9.2.1 New/ Emerging Entrants
3.9.2.2 Mature Players & Leaders
CHAPTER 5 PRODUCTS BUSINESS ANALYSIS
5.1 Creavax
5.1.1 Global Dendritic Cell Cancer Vaccine Market For Creavax, 2018 - 2030 (USD Million)
5.2 Sipuleucel - T (Provenge)
5.2.1 Global Dendritic Cell Cancer Vaccine Market For Sipuleucel - Y (Provenge), 2018 - 2030 (USD Million)
5.3 Others
5.3.1 Global Dendritic Cell Cancer Vaccine Market For Others, 2018 - 2030 (USD Million)
CHAPTER 6 END-USE BUSINESS ANALYSIS
6.1 Pediatrics
6.1.1 Global Dendritic Cell Cancer Vaccine Market For Pediatrics, 2018 - 2030 (USD Million)
6.2 Adults
6.2.1 Global Dendritic Cell Cancer Vaccine Market For Adults, 2018 - 2030 (USD Million)
CHAPTER 8 REGIONAL BUSINESS ANALYSIS
8.1 Dendritic Cell Cancer Vaccine Market: Regional Movement Analysis, 2021 & 2030
8.2 North America
8.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
8.2.3 Canada
8.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3 Europe
8.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.2 Germany
8.3.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
8.3.3 UK
8.3.3.1 UK market estimates and forecast, 2018 - 2030 (USD Million)
8.3.4 France
8.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.5 Italy
8.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.6 Spain
8.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.7 Denmark
8.3.7.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.8 Sweden
8.3.8.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3.8 Norway
8.3.8.1 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4 Asia - Pacific
8.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.2 Japan
8.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.3 China
8.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.4 India
8.4.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.5 Australia
8.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.6 Thailand
8.4.5.1 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.4.6 South Korea
8.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5 Latin America (Latam)
8.5.1 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.5.4 Argentina
8.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6 Middle East and Africa (MEA)
8.6.1 Middle East And Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.4 Uae
8.6.4.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.6.4 Kuwait
8.6.4.1 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
CHAPTER 9 COMPANY PROFILES
9.1 Company Profiles
9.1.1 3M COMPANY
9.1.1.1 Company Overview
9.1.1.2 Financial Performance
9.1.1.3 Product Benchmarking
9.1.1.4 Strategic Initiatives
9.1.2 GLAXOSMITHKLINE PLC
9.1.2.1 Company Overview
9.1.2.2 Financial Performance
9.1.2.3 Product Benchmarking
9.1.2.4 Strategic Initiatives
9.1.3 ACTIVARTIS
9.1.3.1 Company Overview
9.1.3.2 Financial Performance
9.1.3.3 Product Benchmarking
9.1.3.4 Strategic Initiatives
9.1.4 BATAVIA BIOSERVICES
9.1.4.1 Company Overview
9.1.4.2 Financial Performance
9.1.4.3 Product Benchmarking
9.1.4.4 Strategic Initiatives
9.1.5 ARGOS THERAPEUTICS
9.1.5.1 Company Overview
9.1.5.2 Financial Performance
9.1.5.3 Product Benchmarking
9.1.5.4 Strategic Initiatives
9.1.6 SANPOWER CORPORATION
9.1.6.1 Company Overview
9.1.6.1 Financial Performance
9.1.6.2 Product Benchmarking
9.1.6.3 Strategic Initiatives
9.1.7 ELIOS THERAPEUTICS
9.1.7.1 Company Overview
9.1.7.2 Financial Performance
9.1.7.3 Product Benchmarking
9.1.7.4 Strategic Initiatives
9.1.8 DANDRIT BIOTECH
9.1.8.1 Company Overview
9.1.8.2 Financial Performance
9.1.8.3 Product Benchmarking
9.1.8.4 Strategic Initiatives
9.1.9 DCPRIME
9.1.9.1 Company Overview
9.1.9.2 Financial Performance
9.1.9.3 Product Benchmarking
9.1.9.4 Strategic Initiatives
9.1.10 IMMUNOCELLULAR THERAPEUTICS
9.1.10.1 Company Overview
9.1.10.2 Financial Performance
9.1.10.3 Product Benchmarking
9.1.10.4 Strategic Initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Incidence of Diseases
Table 4 Global Dendritic Cell Cancer Vaccine Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 6 Global Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 7 North America Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 9 North America Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 10 U.S. Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 11 U.S. Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 12 Canada Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 13 Canada Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 14 Europe Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 15 Europe Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 16 Europe Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 17 Germany Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 18 Germany Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 19 U.K. Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 20 U.K. Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 21 France Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 22 France Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 23 Italy Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 24 Italy Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 25 Spain Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 26 Spain Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 27 Denmark Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 28 Denmark Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 29 Sweden Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 30 Sweden Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 31 Norway Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 32 Norway Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 33 Asia Pacific Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 36 Japan Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 37 Japan Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 38 China Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 39 China Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 40 India Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 41 India Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 42 Australia Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 43 Australia Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 44 Thailand Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 45 Thailand Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 46 South Korea Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 47 South Korea Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 48 Latin America Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 49 Latin America Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 50 Latin America Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 51 Mexico Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 52 Mexico Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 53 Argentina Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 54 Argentina Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 55 Middle East & Africa Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 60 South Africa Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 61 South Africa Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 62 UAE Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 63 UAE Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 64 Kuwait Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 65 Kuwait Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Incidence of Diseases
Table 4 Global Dendritic Cell Cancer Vaccine Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 6 Global Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 7 North America Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 9 North America Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 10 U.S. Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 11 U.S. Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 12 Canada Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 13 Canada Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 14 Europe Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 15 Europe Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 16 Europe Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 17 Germany Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 18 Germany Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 19 U.K. Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 20 U.K. Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 21 France Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 22 France Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 23 Italy Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 24 Italy Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 25 Spain Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 26 Spain Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 27 Denmark Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 28 Denmark Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 29 Sweden Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 30 Sweden Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 31 Norway Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 32 Norway Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 33 Asia Pacific Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 36 Japan Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 37 Japan Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 38 China Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 39 China Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 40 India Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 41 India Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 42 Australia Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 43 Australia Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 44 Thailand Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 45 Thailand Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 46 South Korea Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 47 South Korea Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 48 Latin America Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 49 Latin America Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 50 Latin America Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 51 Mexico Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 52 Mexico Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 53 Argentina Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 54 Argentina Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 55 Middle East & Africa Dendritic Cell Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 60 South Africa Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 61 South Africa Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 62 UAE Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 63 UAE Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
Table 64 Kuwait Dendritic Cell Cancer Vaccine Market, By Product, 2018 - 2030 (USD Million)
Table 65 Kuwait Dendritic Cell Cancer Vaccine Market, By End-use, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Dendritic Cell Cancer Vaccine Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 10 Penetration & Growth Prospect Mapping
Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 12 Porter’s Five Forces Analysis
Fig. 13 Market Penetration Vs Growth Prospect Mapping, 2021
Fig. 14 Dendritic Cell Cancer Vaccine Market: Product Key Takeaways
Fig. 15 Global Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 16 Global Dendritic Cell Cancer Vaccine Market, for Products, 2018 - 2030 (USD Million)
Fig. 17 Global Dendritic Cell Cancer Vaccine Market, for CereVax, 2018 - 2030 (USD Million)
Fig. 18 Global Dendritic Cell Cancer Vaccine Market, for Sipuleucel - T (Provenge), 2018 - 2030 (USD Million)
Fig. 19 Global Dendritic Cell Cancer Vaccine Market, for others, 2018 - 2030 (USD Million)
Fig. 20 Global Dendritic Cell Cancer Vaccine Market, for End-use, 2018 - 2030 (USD Million)
Fig. 21 Global Dendritic Cell Cancer Vaccine Market, for Paediatrics, 2018 - 2030 (USD Million)
Fig. 22 Global Dendritic Cell Cancer Vaccine Market, for Adults, 2018 - 2030 (USD Million)
Fig. 23 Global Dendritic Cell Cancer Vaccine Market - Regional Outlook, 2021 & 2030
Fig. 24 North America Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 25 U.S. Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 26 Canada Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 27 Europe Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 28 Germany Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 29 UK Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 30 France Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 31 Italy Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 32 Spain Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 33 Denmark Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 34 Sweden Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 35 Norway Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 36 Asia Pacific Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 37 Japan Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 38 China Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 39 India Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 40 Australia Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 41 Thailand Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 42 South Korea Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 43 Latin America Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 44 Brazil Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 45 Mexico Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 46 Argentina Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 47 Middle East and Africa Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 48 South Africa Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 49 Saudi Arabia Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 50 UAE Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 51 Kuwait Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Dendritic Cell Cancer Vaccine Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 10 Penetration & Growth Prospect Mapping
Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 12 Porter’s Five Forces Analysis
Fig. 13 Market Penetration Vs Growth Prospect Mapping, 2021
Fig. 14 Dendritic Cell Cancer Vaccine Market: Product Key Takeaways
Fig. 15 Global Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 16 Global Dendritic Cell Cancer Vaccine Market, for Products, 2018 - 2030 (USD Million)
Fig. 17 Global Dendritic Cell Cancer Vaccine Market, for CereVax, 2018 - 2030 (USD Million)
Fig. 18 Global Dendritic Cell Cancer Vaccine Market, for Sipuleucel - T (Provenge), 2018 - 2030 (USD Million)
Fig. 19 Global Dendritic Cell Cancer Vaccine Market, for others, 2018 - 2030 (USD Million)
Fig. 20 Global Dendritic Cell Cancer Vaccine Market, for End-use, 2018 - 2030 (USD Million)
Fig. 21 Global Dendritic Cell Cancer Vaccine Market, for Paediatrics, 2018 - 2030 (USD Million)
Fig. 22 Global Dendritic Cell Cancer Vaccine Market, for Adults, 2018 - 2030 (USD Million)
Fig. 23 Global Dendritic Cell Cancer Vaccine Market - Regional Outlook, 2021 & 2030
Fig. 24 North America Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 25 U.S. Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 26 Canada Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 27 Europe Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 28 Germany Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 29 UK Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 30 France Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 31 Italy Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 32 Spain Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 33 Denmark Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 34 Sweden Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 35 Norway Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 36 Asia Pacific Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 37 Japan Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 38 China Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 39 India Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 40 Australia Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 41 Thailand Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 42 South Korea Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 43 Latin America Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 44 Brazil Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 45 Mexico Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 46 Argentina Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 47 Middle East and Africa Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 48 South Africa Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 49 Saudi Arabia Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 50 UAE Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
Fig. 51 Kuwait Dendritic Cell Cancer Vaccine Market, 2018 - 2030 (USD Million)
